OHR 1601

Status: Ongoing, but not recruiting participants

ClinicalTrials.gov Identifier: NCT02727881

OHR 1601: A Phase III study of Efficacy and Safety of Squalamine Lactate Opthalmic Solution, 0.2% twice daily in subjects with Neovascular AMD.

Condition: Age-Related Macular Degeneration

Study Type: Interventional

Duration: 2 years

Eligibility:

  • Ages: 50 years to 110 years
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.